All In Biotech

Drug Trial Radar · NCT04136366

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

The GUARD Trial - Part 1: A Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 Versus Standard-of-Care for Prevention of Proliferative Vitreoretinopathy

Last checked: Nov 19, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

106

Actual

Start

Nov 15, 2019

Primary completion

Jun 14, 2022

Study completion Jun 14, 2022

Sponsor

Lead sponsor
Aldeyra Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.

Conditions

  • Proliferative Vitreoretinopathy

Interventions

  • ADX-2191 (intravitreal methotrexate 0.8%)Drug

    ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy

  • Standard surgical care procedureOther

    Standard surgical care performed upon completion of pars plana vitrectomy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrent Retinal Detachment Compared to Historical RatesTime frame: Efficacy assessment period (Week 1 to Week 24)

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Retinal Consultants of Arizona

    Phoenix, Arizona

  • University of California Los Angeles

    Los Angeles, California

  • Florida Retina Institute

    Orlando, Florida

  • Bascom Palmer Eye Institute

    Palm Beach Gardens, Florida

  • Emory Eye Center

    Atlanta, Georgia

  • University of Illinois at Chicago

    Chicago, Illinois

  • Illinois Retina Associates

    Joliet, Illinois

  • University of Iowa

    Iowa City, Iowa

  • Tufts Medical Center

    Boston, Massachusetts

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • Massachusetts Eye and Ear

    Boston, Massachusetts

  • New England Retina Consultants

    Springfield, Massachusetts

  • Kresge Eye Institute

    Detroit, Michigan

  • Associated Retinal Consultants

    Royal Oak, Michigan

  • Vitreo-Retinal Surgery

    Minneapolis, Minnesota

  • Mayo Clinic Ophthalmology

    Rochester, Minnesota

  • The Retina Institute

    St Louis, Missouri

  • Long Island VitreoRetinal Consultants

    Forest Hills, New York

  • Duke Health Center

    Durham, North Carolina

  • OHSU Casey Eye Institute

    Portland, Oregon

  • Mid Atlantic Retina

    Philadelphia, Pennsylvania

  • Retina Consultants of Houston

    Houston, Texas

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.